JWJoachim Worthington

Joachim Worthington

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joachim Worthington has a total of 113 co-authors. Here are the top co-authors by number of shared publications:

  • Eleonora Feletto

    The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia

    11 shared publications
  • Karen Canfell

    University of Sydney Sydney NSW

    11 shared publications
  • Eleonora Feletto

    The Cancer Elimination Collaboration, School of Public Health, The University of Sydney, Australia; The Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, Australia

    9 shared publications
  • Emily He

    The Cancer Elimination Collaboration, School of Public Health, The University of Sydney, Australia; The Daffodil Centre, The University of Sydney, and Cancer Council NSW, Sydney, Australia

    8 shared publications
  • Holger R. Dullin

    School of Mathematics and Statistics, University of Sydney, Sydney, Australia

    8 shared publications
  • Jie-Bin Lew

    Sydney School of Public Health, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia

    8 shared publications

Latest Publications

  • Open Access

    A New Integrative Modeling Approach for Generating Counterfactual Projections of Colorectal Cancer Incidence Rates in the Absence of Organized Screening in Australia

    by Qingwei Luo, Jie-Bin Lew, Joachim Worthington, Clare Kahn, Han Ge, Emily He, Michael Caruana, Michael David, Dianne L O’COnnell, Karen Canfell, et al.

    Background: The Australian National Bowel Cancer Screening Program (NBCSP), which provides 2-yearly screening to people aged 50 to 74 y, had a phased rollout from 2006 and was fully implemented in 2020. To measure the effectiveness of the NBCSP accounting for age-specific trends, we aimed to develop a novel integrative method to project colorectal cancer (CRC) incidence rates from 2006 to 2045 in the absence of the NBCSP (referred to as “no-NBCSP projections”) while addressing the challenge of complex age-specific trends in CRC incidence. Methods: We constructed a new dataset by replacing the observed data for NBCSP-eligible individuals aged 50 to 74 y with intermediate projections based on pre-NBCSP data from 1982 to 2005. We compared the no-NBCSP CRC incidence projected using a standard age-period-cohort (APC) model, age-stratified APC models, and the integrative modeling approach. Results: The integrative modeling approach captured complex age-specific trends better than the standard and age-stratified APC models did. Without the NBCSP, the overall CRC incidence rates would be expected to decline from 2005 to 2025, followed by increases from 2026 to 2045. The incidence rates for those aged <50 y would be projected to continue increasing to 2045, and an increase in incidence rates for older age groups would be projected to occur from 2020 for ages 50 to 54 y, from 2030 for ages 65 to 74 y, and from 2035 for ages 75 y and older. Conclusions: These no-NBCSP projections provide a counterfactual benchmark against which to measure the impact of the NBCSP on CRC incidence in Australia, and they have been used as new calibration targets for a simulation model of CRC and screening in Australia. The methods developed here could be used to generate comparators to assess the impact of other public health interventions. Highlights: We constructed counterfactual projections of colorectal cancer (CRC) incidence rates in the absence of the National Bowel Cancer Screening Program (no-NBCSP projections). To do this, we developed a new integrative modeling approach to capture complex age-specific colorectal cancer incidence trends. These no-NBCSP projections provide a counterfactual benchmark against which to measure the impact of the NBCSP on CRC incidence in Australia. These projections stress the need for ongoing assessment of the starting age for the NBCSP, to tackle the increasing incidence for people younger than 50 y.


  • Open Access

    Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia: summary of recommendations

    by Jacob George, Nicole L Allard, Stuart K Roberts, Leon A Adams, Jane Davies, Behzad Hajarizadeh, Jennifer H MacLachlan, Suzanne E Mahady, Rosalie Altus, Catherine Brown, et al.

    Introduction: Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, the sixth most common cause of cancer death in Australia. With shifting aetiologies and a growing at‐risk population, consistent routine surveillance recommendations are key to early detection of HCC and improved survival. We developed new evidence‐based HCC surveillance guidelines for people at high risk in Australia due to liver disease and/or other risk factors. These guidelines were developed by a working group of experts in liver cancer control and included evidence reviews, synthesis and adaptation of existing guidelines for the Australian context, and predictive modelling.Main recommendations: This article summarises the recommendations and practice points for key population subgroups who were identified as potentially benefitting from routine HCC surveillance in the form of six‐monthly ultrasound scans, with or without α‐fetoprotein testing. People with liver cirrhosis and a non‐HCC‐related life expectancy of greater than six months are recommended to receive routine HCC surveillance. People with chronic hepatitis B virus infection who do not have liver cirrhosis are recommended to receive routine HCC surveillance if they have a family history of HCC, are Aboriginal or Torres Strait Islander peoples, or have an Asian, Pacific, or sub‐Saharan African background, with varying start ages recommended for each group. People with stage 3 non‐cirrhotic liver fibrosis (F3) may be recommended to receive routine HCC surveillance based on individual risk assessment, or otherwise monitored for progression to cirrhosis. The final guidelines were approved by the National Health and Medical Research Council (NHMRC) in April 2023.Changes in management as a result of the guideline: The updated guidelines formalise recommendations for people with cirrhosis, identify other patient groups who are recommended for surveillance, and highlight gaps in evidence where the benefit of surveillance is unclear. These guidelines were accompanied by the Roadmap to liver cancer control, a coordinated ten‐year plan for advancing liver cancer prevention and early detection in Australia. The full guidelines can be accessed at https://cancer.org.au/clinical‐guidelines/liver‐cancer/hepatocellular‐carcinoma.


  • Open Access

    Evaluating Semi-Markov Processes and Other Epidemiological Time-to-Event Models by Computing Disease Sojourn Density as Partial Differential Equations

    by Joachim Worthington, Eleonora Feletto, Emily He, Stephen Wade, Barbara de Graaff, Anh Le Tuan Nguyen, Jacob George, Karen Canfell, Michael Caruana

    Introduction: Epidemiological models benefit from incorporating detailed time-to-event data to understand how disease risk evolves. For example, decompensation risk in liver cirrhosis depends on sojourn time spent with cirrhosis. Semi-Markov and related models capture these details by modeling time-to-event distributions based on published survival data. However, implementations of semi-Markov processes rely on Monte Carlo sampling methods, which increase computational requirements and introduce stochastic variability. Explicitly calculating the evolving transition likelihood can avoid these issues and provide fast, reliable estimates. Methods: We present the sojourn time density framework for computing semi-Markov and related models by calculating the evolving sojourn time probability density as a system of partial differential equations. The framework is parametrized by commonly used hazard and models the distribution of current disease state and sojourn time. We describe the mathematical background, a numerical method for computation, and an example model of liver disease. Results: Models developed with the sojourn time density framework can directly incorporate time-to-event data and serial events in a deterministic system. This increases the level of potential model detail over Markov-type models, improves parameter identifiability, and reduces computational burden and stochastic uncertainty compared with Monte Carlo methods. The example model of liver disease was able to accurately reproduce targets without extensive calibration or fitting and required minimal computational burden. Conclusions: Explicitly modeling sojourn time distribution allows us to represent semi-Markov systems using detailed survival data from epidemiological studies without requiring sampling, avoiding the need for calibration, reducing computational time, and allowing for more robust probabilistic sensitivity analyses. Highlights: Time-inhomogeneous semi-Markov models and other time-to-event–based modeling approaches can capture risks that evolve over time spent with a disease. We describe an approach to computing these models that represents them as partial differential equations representing the evolution of the sojourn time probability density. This sojourn time density framework incorporates complex data sources on competing risks and serial events while minimizing computational complexity.


  • Open Access

    Recalibrating an Established Microsimulation Model to Capture Trends and Projections of Colorectal Cancer Incidence and Mortality

    by Jie-Bin Lew, Qingwei Luo, Joachim Worthington, Han Ge, Emily He, Julia Steinberg, Michael Caruana, Dianne L. O’cOnnell, Eleonora Feletto, Karen Canfell

    Background: Changing colorectal cancer (CRC) incidence rates, including recent increases for people younger than 50 y, need to be considered in planning for future cancer control and screening initiatives. Reliable estimates of the impact of changing CRC trends on the National Bowel Cancer Screening Program (NBCSP) are essential for programmatic planning in Australia. An existing microsimulation model of CRC, Policy1-Bowel , was updated to reproduce Australian CRC trends data and provide updated projections of CRC- and screening-related outcomes to inform clinical practice guidelines for the prevention of CRC. Methods: Policy1-Bowel was recalibrated to reproduce statistical age-period-cohort model trends and projections of CRC incidence for 1995–2045 in the absence of the NBCSP as well as published data on CRC incidence trends, stage distribution, and survival in 1995–2020 in Australia. The recalibrated Policy1-Bowel predictions were validated by comparison with published Australian CRC mortality trends for 1995–2015 and statistical projections to 2040. Metamodels were developed to aid the calibration process and significantly reduce the computational burden. Results: Policy1-Bowel was recalibrated, and best-fit parameter sets were identified for lesion incidence, CRC stage progression rates, detection rates, and survival rates by age, sex, bowel location, cancer stage, and birth year. The recalibrated model was validated and successfully reproduced observed CRC mortality rates for 1995–2015 and statistical projections for 2016–2030. Conclusion: The recalibrated Policy1-Bowel model captures significant additional detail on the future incidence and mortality burden of CRC in Australia. This is particularly relevant as younger cohorts with higher CRC incidence rates approach screening ages to inform decision making for these groups. The metamodeling approach allows fast recalibration and makes regular updates to incorporate new evidence feasible. Highlights: In Australia, colorectal cancer incidence rates are increasing for people younger than 50 y but decreasing for people older than 50 y, and colorectal cancer survival is improving as new treatment technologies emerge. To evaluate the future health and economic impact of screening and inform policy, modeling must include detailed trends and projections of colorectal cancer incidence, mortality, and diagnosis stage. We used novel techniques including integrative age-period cohort projections and metamodel calibration to update Policy1-Bowel , a detailed microsimulation of colorectal cancer and screening in Australia.


  • Open Access

    A Health Economic Evaluation of Routine Hepatocellular Carcinoma Surveillance for People with Compensated Cirrhosis to Support Australian Clinical Guidelines

    by Joachim Worthington, Emily He, Michael Caruana, Stephen Wade, Barbara de Graaff, Anh Le Tuan Nguyen, Jacob George, Karen Canfell, Eleonora Feletto

    Background. Liver cancer is the only cancer in Australia with rising incidence and mortality rates, despite the potential for early detection through surveillance of high-risk individuals. Hepatocellular carcinoma (HCC), the most common form of primary liver cancer, has curative treatment options available if detected early. Six-monthly HCC surveillance is recommended for people with liver cirrhosis and was proposed for inclusion in the 2023 Cancer Council Australia Clinical Practice Guidelines for Hepatocellular Carcinoma Surveillance for People at High Risk in Australia . To evaluate the proposed 2023 guideline recommendation, we developed Policy1-Liver, a novel mathematical model of liver disease, HCC, and surveillance. We then assessed the health and economic implications of 6-monthly HCC surveillance in Australia via ultrasound, with or without alpha-fetoprotein. Methods. Policy1-Liver was calibrated to existing data sources on liver disease, HCC, and health care costs in Australia. We assessed the impact of 6-monthly routine HCC surveillance with ultrasound with or without alpha-fetoprotein testing as well as a range of other sensitivity analyses and alternative scenarios such as varying surveillance adherence and intervals to assess potential future modifications to surveillance. Results. We estimated that 6-monthly HCC surveillance, with or without alpha-fetoprotein, can increase early-stage diagnoses to up to 81% and reduce HCC mortality by 22% in people with cirrhosis. We estimate an incremental cost-effectiveness ratio of $28,423 per quality-adjusted life-year for 6-monthly surveillance with ultrasound alone compared with no surveillance. Conclusions. These findings support guideline-recommended 6-monthly HCC surveillance with ultrasound, affirming its health benefits and cost-effectiveness, and demonstrate the potential to improve cost-effectiveness by refining surveillance intervals and improving early-stage HCC survival. Supporting implementation of the surveillance guidelines will play a key role in improving HCC mortality rates in Australia. Highlights: Routine surveillance can improve the likelihood of early-stage detection of liver cancer, improving survival. Our modeling found that routine HCC surveillance with ultrasound would be cost-effective for people with liver cirrhosis in Australia. These findings can inform guidelines and investment in liver cancer control for high-risk patients.